Deep Brain Stimulation for Speech Sequencing in Parkinson's Disease

This trial aims to understand how deep brain stimulation (DBS) affects speech learning and production in people with Parkinson's disease and essential tremor. Researchers are examining how two brain areas, the subthalamic nucleus (STN) and the ventral intermediate nucleus of the thalamus (VIM), assist in learning new speech sequences. Participants will perform speech tasks with their DBS devices turned on or off to observe the influence on their ability to learn and produce speech. Individuals with Parkinson’s or essential tremor who have DBS devices and stable treatment plans might be suitable candidates. The insights gained could lead to improved DBS settings that enhance both movement and speech for people with these conditions. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could advance DBS therapy for speech and movement.

The trial requires that your Parkinson's disease or essential tremor medication regimen be stable for at least one month before participating. This means you should not change your current medications during the trial.

Research has shown that deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) is generally safe for treating Parkinson's disease. Studies have found it effective in improving movement problems with a low risk of serious side effects. For instance, one study reported significant improvements in movement over five years while maintaining safety.

Similarly, DBS targeting the ventral intermediate nucleus (VIM) of the thalamus is considered safe and effective, particularly for controlling tremors in conditions like essential tremor. Research indicates that VIM-DBS successfully reduces tremor symptoms without major side effects.

Researchers are excited about this trial because it's exploring how deep brain stimulation (DBS) might improve speech sequencing in individuals with Parkinson's disease. Unlike standard treatments, which often focus on dopamine replacement and managing symptoms with medication, this trial uses DBS to potentially enhance brain function directly. By targeting specific brain areas—the subthalamic nucleus and the ventral intermediate thalamus—while subjects engage in language learning tasks, researchers hope to uncover new insights into how DBS can be used to support speech production. This approach could lead to breakthroughs in improving speech and communication, offering new hope for people with Parkinson's.

Research has shown that deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) can improve speech and voice quality in people with Parkinson's disease. In this trial, some participants will receive STN-DBS while engaging in learning tasks involving either non-English sound sequences or syllable sequences. Some studies suggest that STN-DBS can help restore certain speech patterns, although its effects on speech fluency can vary.